ProceduralSurgical principlesProcedural / governance
Anticoagulation management for skin surgery
Perioperative anticoagulation · antiplatelet bridging · DOAC management
Skin surgery is a low-bleeding-risk procedure for most patients. UK BSH, NICE NG89 and BSDS antithrombotic guidance support the principle that single-agent antiplatelet therapy, most DOACs and therapeutic-range warfarin should not be stopped routinely before skin-cancer surgery, because the thromboembolic risk of stopping can exceed the haemorrhagic risk of continuing. The advice should still be individualised: large flaps, grafts, lymphadenectomy, free flaps, difficult haemostasis sites and patients on treatment for low-risk indications may justify planned interruption after thrombotic-risk review.
CurrentLast reviewed 7 June 2026
Principle
- Skin surgery is low-haemorrhagic-risk: visible incision allows direct haemostasis; consequences of bleeding are usually cosmetic / cutaneous rather than catastrophic.
- Thromboembolic events on holding anticoagulation (stroke, MI, VTE, stent thrombosis) carry far higher morbidity and mortality.
- Default position: continue single-agent antiplatelet / warfarin / DOAC for most low- and moderate-bleeding-risk skin-cancer surgery.
- Exception: for high bleeding-consequence surgery (large flap, graft, lymph-node surgery, free flap, difficult-to-compress site), document a patient-specific decision. Planned interruption is reasonable when thromboembolic risk is low and the bleeding consequence is judged clinically important.
- Document risk-benefit discussion in clinic letter and procedure consent.
Specific agents
| Agent | Standard advice for skin surgery |
|---|---|
| Aspirin | Continue for secondary prevention. If used only for primary prevention and the planned reconstruction has meaningful bleeding consequences, consider stopping 7-10 days pre-op after documenting the risk-benefit discussion. |
| Clopidogrel / prasugrel / ticagrelor | Continue when thrombotic risk is high, especially recent ACS or coronary stent. For elective high-bleeding-consequence reconstruction in a lower-risk patient, discuss with the prescriber / cardiology; typical interruption is clopidogrel 5 days, ticagrelor 5 days, prasugrel 7 days. |
| Dual antiplatelet therapy (DAPT) | Avoid stopping without cardiology advice. Delay elective complex surgery until the single-antiplatelet phase when possible. |
| Warfarin | Continue for most skin surgery if INR is within the intended therapeutic range. For selected high-bleeding-consequence graft / flap surgery in a low-thromboembolic-risk patient, planned interruption can be considered with the anticoagulation clinic / prescriber; typical interruption is 5 days with INR check before surgery. Bridging is not routine for low-risk AF. |
| DOAC (apixaban, rivaroxaban, edoxaban, dabigatran) | Continue for most minor skin surgery. For higher-bleeding-risk procedures, consider omitting the morning dose or holding 24 hours; consider 48 hours for higher bleeding risk, renal impairment or dabigatran. Restart when haemostasis is secure. |
| LMWH (enoxaparin / dalteparin / tinzaparin) | Continue prophylactic-dose LMWH for most cases. For treatment-dose LMWH, omit the dose closest to surgery and restart once haemostasis is secure; use haematology / anticoagulation advice for high-thrombotic-risk patients. |
| Herbal / OTC bleeding-risk agents (ginkgo, garlic, ginseng, fish oil, vitamin E, NSAIDs) | Stop non-essential agents if the patient can safely do so: NSAID timing depends on the drug; herbal / supplement agents are commonly stopped about 1 week pre-procedure. |
High-thromboembolic-risk situations
- Mechanical heart valve.
- Recent VTE (<3 months).
- Atrial fibrillation with CHA2DS2-VASc ≥4 or prior stroke.
- Recent acute coronary syndrome (<12 months).
- Recent coronary stent — bare-metal <1 month, drug-eluting <12 months on DAPT.
- Active malignancy with thrombosis.
- Antiphospholipid syndrome.
For these, do not interrupt anticoagulation without explicit cardiology / haematology / specialist advice; bridging with LMWH may be needed for warfarin in valve patients.
Intraoperative haemostasis
- Adrenaline-containing LA (1:100 000 or 1:200 000).
- Meticulous bipolar / monopolar diathermy or ligation of named vessels.
- Topical haemostats: kaolin / ferric sulphate (small biopsy), oxidised cellulose (Surgicel), gelatin-thrombin matrix (Floseal), bone wax for periosteum, fibrin glue.
- Compression / packing; tie-over bolster.
- NPWT closed-incision dressing for tension closures.
- Closed suction drainage for large flap / wide excision.
Practical points
- Pre-procedure document: indication, anticoagulant, indication for anticoagulation, target INR where relevant, last dose timing, thromboembolic risk and planned restart.
- Counsel patient about potential post-op bleeding, head-elevation, ice packs, pressure dressing, when to contact the team.
- Consider day-case rather than evening / weekend timing for higher-risk cases (access to plastics on-call).
- Post-op clear written instructions; emergency contact.
- For Mohs: minor adjustments per defect size; for elective major reconstruction, consider anaesthetic / haematology / cardiology input where interruption is contemplated.
- Avoid intramuscular injections, deep field blocks in fully anticoagulated patients.
References
- Keeling D et al. Peri-operative management of anticoagulation and antiplatelet therapy. Br J Haematol. 2016;175:602-613.
- NICE NG89. Venous thromboembolism in over 16s: reducing the risk of hospital-acquired deep vein thrombosis or pulmonary embolism. London: NICE; 2018 (last updated 13 August 2019; reviewed 18 September 2024).
- Alcalay J, Alkalay R. Controversies in perioperative management of blood thinners in dermatologic surgery. Dermatol Surg. 2004;30:1091-1094.
- British Society for Dermatological Surgery. Guidance on antithrombotics and skin surgery. London: BSDS; 2023.
- Bordeaux JS, Martires KJ, Goldberg D et al. Prospective evaluation of dermatologic surgery complications including patients on multiple antiplatelet and anticoagulant medications. J Am Acad Dermatol. 2011;65:576-583.
Spot a correction?
If any clinical statement, citation or link on this page needs updating, please email admin@skinoncology.net with the page name, the proposed correction and the supporting source.